• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Adebrelimab plus chemotherapy improves overall survival in extensive-stage small-cell lung cancer

byJohan PushaniandSze Wah Samuel Chan
May 23, 2022
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The adebrelimab group had an improved overall survival, higher objective response rate and an increased progression-free survival.

2. Adverse events were similar in both groups, with the most common treatment-related grade 3 or 4 ones being decreased neutrophil count, decreased white blood cell count, anemia, and decreased platelet count.

Evidence Rating Level: 1 (Excellent)

Study Rundown: While current treatment frameworks for extensive-stage small-cell lung cancer (ES-SCLC) tend to involve immunotherapy, various agents have shown different efficacy outcomes. This study explored the use of adebrelimab (a novel humanized IgG4 monoclonal antibody against PD-L1) on patients with untreated ES-SCLC. Patients were randomly assigned to receive carboplatin and etoposide, with either adebrelimab or placebo. In the adebrelimab group, there was an increased median overall survival (OS), increased progression-free survival (PFS) rates, and higher objective response rates (ORR). Treatment-related adverse events of grade 3 or 4 occurred with similar frequency in both groups, with the most common category being hematological events such as decreased neutrophil count, decreased white blood cell count, anemia, and decreased platelet count. Occurrence of treatment-related serious adverse events was slightly higher in the adebrelimab group. Limitations to this study include its generalizability as it only included patients from China, and that it only used one biomarker for survival. The strength of this study is that it provides a treatment option to ES-SCLC patients, which currently have a poor prognosis and limited treatment options. Overall, this study showed the clinical benefits of adebrelimab and supports its viability as a first-line treatment option.

Click to read the study in The Lancet Oncology

Relevant Reading: Small cell lung cancer (SCLC): no treatment advances in recent years

RELATED REPORTS

#VisualAbstract: Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC

Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC

Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma

In-Depth [randomized control trial]: This multicenter phase III trial was done in 47 tertiary hospitals in China. Patients were randomly assigned to receive carboplatin and etoposide, with either adebrelimab or placebo; 230 were in the adebrelimab group and 232 were in the placebo group. Median OS was 15.3 months in the adebrelimab group and 12.8 months in the placebo group (hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.0017). PFS rate at 6 and 12 months in the adebrelimab group was 49.4% (95% CI, 42.4 to 56.0) and 19.7% (14.5 to 25.5), respectively, compared to 37.3% (30.7 to 43.9) and 5.9% (3.1 to 10.1) in the placebo group, respectively. The proportion of patients with an ORR in the adebrelimab group was 70.4% (95% CI, 64.1 to 76.3) and 65.9% (59.5 to 72.0) in the placebo group. Treatment-related grade 3 or worse adverse events occurred in 86% and 85% of patients in the adebrelimab and placebo groups, respectively. The most common adverse events across both groups were decreased neutrophil count (76% in the adebrelimab group and 75% in the placebo group), decreased white blood cell count (46% and 38%, respectively), decreased platelet count (38% and 34%, respectively), and anemia (28% and 28%, respectively). Occurrence of treatment-related serious adverse events was 39% and 28% in adebrelimab and placebo groups, respectively. Frequency of hematological adverse events was higher across both groups when indirectly compared to other immunochemotherapy agents, though this may be attributed to a higher susceptibility to such events from chemotherapy in Asian patients. Overall, adebrelimab plus chemotherapy significantly improved overall survival and showed an acceptable safety profile in ES-SCLC patients.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adebrelimabextensive SCLCPD-1
Previous Post

Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer

Next Post

Gratitude-focused writing may improve mental wellness during periods of chronic stress

RelatedReports

#VisualAbstract: Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC
StudyGraphics

#VisualAbstract: Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC

December 14, 2023
Patient Basics: Lung Cancer Overview
Oncology

Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC

December 11, 2023
Resection of colorectal liver metastases may improve cost and longevity
Oncology

Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma

December 21, 2021
Next Post
Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse

Gratitude-focused writing may improve mental wellness during periods of chronic stress

Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

Operating the day after performing surgery the previous night not associated with adverse patient outcomes

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.